From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

The ASCO Post

Study Examines Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer

2022 ASCO Annual Meeting

The Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients With Locally Recurrent or Metastatic Triple-Negative Breast Cancer

2022 ASCO Annual Meeting

Apatinib Plus Etoposide as Second- or Higher-Line Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Single-Arm, Open Label, Prospective, Phase II Clinical Trial

2022 ASCO Annual Meeting

Treatment Advances in Metastatic Triple-Negative Breast Cancer (TNBC): Addressing the Knowledge Gap

2022 ASCO Annual Meeting

Real-World Data Comparing Third and Subsequent Line Regimens for Treatment of Metastatic Triple-Negative Breast Cancer in the United States

Epidemiology

Outcome of Patients With Metastatic Triple Negative Breast Cancer Treated With First-Line Chemotherapy: A Single Institution Retrospective Analysis

JNCCN

Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer

Cancer and Metastasis Review

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

World Journal of Clinical Oncology

Overview of Recent Advances in Metastatic Triple Negative Breast Cancer

International Journal of Molecular Sciences

Multi-Gene Testing Overview With a Clinical Perspective in Metastatic Triple-Negative Breast Cancer

Journal of Oncology Pharmacy Practice

Case Report of Sacituzumab Govitecan-hziy-Induced Neutropenia in a Patient With Metastatic Triple-Negative Breast Cancer and a Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 Poor Metabolizer Genotype

Scientific Reports

Addition of Immune Checkpoint Inhibitors to Chemotherapy Versus Chemotherapy Alone in First-Line Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

Nature Reviews Clinical Oncology

Immune-Checkpoint Inhibition for Metastatic Triple-Negative Breast Cancer: Safety First?

ESMO Open

How I Treat Metastatic Triple-Negative Breast Cancer

Breast Cancer: Targets and Therapy

Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

New England Journal of Medicine

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Asia-Pacific Journal of Clinical Oncology

Metastatic Triple Negative Breast Cancer: Optimizing Treatment Options, New and Emerging Targeted Therapies

The ASCO Post

KEYNOTE-355 Final Analysis Reveals Survival Benefit With Pembrolizumab in Triple-Negative Breast Cancer

2021 San Antonio Breast Cancer Symposium

Datopotamab Deruxtecan in Advanced/Metastatic HER2- Breast Cancer: Results From the Phase 1 TROPION-Pantumor01 Study

Pharmaceuticals

Immunotherapy Treatment for Triple Negative Breast Cancer

Fast Facts #2: Chemotherapy